PTX : Summary for Pernix Therapeutics Holdings, I - Yahoo Finance

U.S. Markets closed

Pernix Therapeutics Holdings, Inc. (PTX)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.79+0.03 (+1.09%)
At close: 4:00PM EST
People also watch
EBIOXGTIGEVOSPHSSKLN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close2.76
Open2.73
Bid2.51 x 100
Ask3.18 x 100
Day's Range2.71 - 2.87
52 Week Range0.39 - 4.80
Volume172,482
Avg. Volume442,079
Market Cap26.5M
Beta2.04
PE Ratio (TTM)-0.12
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire10 days ago

    Pernix Therapeutics Appoints Ken Piña as General Counsel and Chief Compliance Officer

    MORRISTOWN, N.J., Jan. 06, 2017-- Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company with a focus on pain and CNS conditions, today announced the appointment of Ken Piña as Senior Vice ...

  • Capital Cube10 days ago

    ETFs with exposure to Pernix Therapeutics Holdings, Inc. : January 6, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Pernix Therapeutics Holdings, Inc. Here are 5 ETFs with the largest exposure to PTX-US. Comparing the performance and risk of Pernix Therapeutics Holdings, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q3, 2016 By the Numbers : January 5, 2017
    Capital Cube11 days ago

    Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q3, 2016 By the Numbers : January 5, 2017

    Categories: Yahoo Finance Get free summary analysis Pernix Therapeutics Holdings, Inc. reports financial results for the quarter ended September 30, 2016. Highlights Summary numbers: Revenues of USD 41.47 million, Net Earnings of USD -26.44 million. Gross margins widened from 22.31% to 23.94% compared to the same period last year, operating (EBITDA) margins now 16.33% from 12.71%. Change in ... Read more (Read more...)